Living Donor Liver Transplant



Abhi Humar Professor of Surgery Division of Transplant

Transplant Waiting List



Consequences of Waiting List

What does this mean for the individual patient needing a liver transplant:

- About a 15-25% chance of never making it to transplant.
- Longer waiting times before receiving a transplant
- A more debilitated state by the time a transplant is performed
- A longer and more difficult recovery time posttransplant

- Xenotransplants
- Non-transplant options for end-stage organ failure
- "Marginal donors" or "expanded criteria donors"
- Living donor transplants
- Split liver transplants from a deceased donor

Advantages and Disadvantages of LDLTx

Disadvantages

Short-term risks to donor
Long-term risks to donor
Increased incidence of biliary and vascular complications
Decreased hepatic reserve

Advantages

Decreased waiting time
Transplant prior to recipient becoming critically ill
Elective, non-emergent
Minimal cold ischemia
Immunologic advantage
Adds to cadaver pool

Donor Selection

Prerequisite for Use of Living Donors

The potential donor must :

- understand the procedure and the risks
- Not be coerced
- Provide a voluntary answer
- Be mentally competent and of legal age.

Donor Evaluation for LRLTx

- Medically fit:
 - H and P
 - LFTs
 - Serological tests
- Surgically fit
- Psychologically fit

Recipient Selection

Recipient Selection for LRLTx

Who?:

• Patients considered suitable for cadaveric transplants

When?

- Circumstances in which there are expectations of recovery for the recipient.
- Ideally patients with MELD>12 and <30</p>



Portion of liver to be used for child transplant Portion of liver to be removed for adult transplant



Right lobe to be resected Volume = 700 cc



Outcomes after ALDLT

Outcomes after LDLT



The Ultimate Sacrifice

A healthy man gives his brother half his liver—and dies. Should this kind of transplant be allowed?

By CHRISTINE GORMAN

IKE AND ADAM HUREWITZ GREW UP together on Long Island, in the suburbs of New York City. They were very close, even for brothers. So when Adam's liver started failing, Mike offered to give him half of his. The operation saved Adam's life. But Mike, who went into the hospital in seemingly excellent health, developed a complication perhaps a blood clot—and died last week. He was 57.

Mike Hurewitz's death has prompted a

like bad odds, but there's more to this ethical dilemma than a simple ratio. The first and most sacred rule of medicine is to do no harm. "For a normal healthy person, a mortality rate of 1% is hard to justify," says Dr. John Fung, chief of transplantation at the University of Pittsburgh Medical Center. "If the rate stays at 1%, it's just not going to be accepted."

On the other hand, there's an acute shortage of traditional donor organs from people who have died in accidents or suffered fatal heart attacks. If family members fully understand the risks and are willing to however, is a lot plant a kidney. N with blood vessel proteins that nee right ratios for th organs from the used, the surgeon the donated live take as much of i goes well, a hea whatever portion sometimes within

A living-donce ularly well when a portion of the live the left lobe of the ing to a mortality the neighborhood But when the reco much as 60% of the removed. "There for error," says D





•Estimated risk of mortality or transplant = 0.5%

Donor Mortality- other organs

Kidney:

- 1999-2001-15,162 donor nephrectomy
- 2 deaths, 1 persistent vegetative state (0.02%)

ATC 2003, Washington DC

A survey of liver transplantation from living adult donors in the United States. Brown RS et al. NEJM 2003; 248:818-25.

Type of complication	Number	%
Death	1	0.2
Need for rehospitilization	38	8.5
Bile stricture or leak	27	6.0
Need for reoperation	20	4.5
Major postoperative infection	5	1.1
Nonautologous blood transfusion	22	4.9
Other	10	2.2
Total	65	14.5

Donor Morbidity in 1841 LDLT donors

• Japanese Liver Transplant Society Database. Lancet 2003.

Graft Type	Morbidity	Biliary Fistula	Reoperation
Left Lateral	8.2	1.9	1.2
Left	12.0	1.9	0.4
Left lobe plus caudate	15.7	3.6	2.9
Right	19.0	10.2	1.8
Total	12.4	4.0	1.2



The Vancouver Forum: Care of the Live Organ Donor

	Europe 2004	USA 2003	Asia 2003	
	1287	449	1508	
	ΛΛΕ		020	
Leit liver.	440	-	939	
mortality	1	-	0	0.07%
morbidity	9 %		9%	9%
Right Liver:	385	449	561	
mortality	3	1	1	0.3%
morbidity	21%	14%	28%	21%

Current overall right lobe donor morbidity: ~35%

Long-term outcomes

- What is the possible impact 10, 20, 30, 40, 50 years down the road?
- What is the incidence of late biliary strictures?
- What is the impact of hepatic regeneration on donor liver issues

Recipients: Risks and Outcomes





Thuluvath, Liver transplantation, 2004

Pomfret, AJT, 2007

Outcomes of 385 Adult-to-Adult Living Donor Liver Transplant Recipients: A Report From the A2ALL Consortium

Olthoff K et al. Ann. Surg. 2005; 242:314-325.

Biliary complications (First Year): Leak 32% Stricture 17% Vascular Complications (First Year) **HAT 6% PVT 3% Reoperation Rate (First Year) 25% Sepsis Rate (First Year) 41%**

13.2% of grafts fail within the first 90 days

Outcomes of 385 Adult-to-Adult Living Donor Liver Transplant Recipients: A Report From the A2ALL Consortium

Center experience > 20 LDALT associated with a lower risk of graft failure.

 Centers with < 20 associated with 83% higher risk of graft failure (p<0.0045)

Recipient MELD score and graft size were not significant predictors of graft loss.

Olthoff K et al. Ann. Surg. 2005; 242:314-325.



"Small-for-Size" Syndrome

Partial liver graft unable to meet the functional demands of the recipient resulting in poor early graft function without evidence of ischemic injury

- Poor bile production
- Prolonged cholestasis
- Significant ascites
- Coagulopathy



In the context of LT, ~ 50% of recipients with SFSS will die of sepsis within 4-6 weeks

Recipient Related Factors

- Recipient factors that predict poor outcome and SFSS:
 - Graft mass
 - Poor metabolic and physical condition
 - Advanced chronic liver disease and severe portal hypertension
 - Impaired venous inflow and/or outflow

Avoidance of Portal Hyperperfusion Syndrome

- Reconstruction of accessory hepatic veins
 - Accessory RHV
 - Segment 5/8 drainage to MHV
- Reducing portal venous inflow
 - Biochemical: prostaglandin E1 (vasodilator and hepatoprotective) and somatostatin
 - Splenic artery ligation
 - Meso-caval shunt
 - Porto-caval shunt

Multivariate Analysis of Risk Factors for patient survival

Risk Factor	Characteristic	Hazard ratio Patient Survival	р
Donor Source	Cad vs LD	4.88	0.04
Graft Type	Partial vs whole	0.77	0.53
MELD score	≥25 vs <25	1.11	0.71
Donor Age	≥50 vs <50	1.38	0.25
Recipient Age	≥50 vs <50	1.19	0.52
Transplant number	Retransplant vs primary	2.71	0.02
Нер С	Yes vs no	1.57	0.09
НСС	Yes vs no	2.48	0.003



